Autonomix Medical (NASDAQ: AMIX) has received a new U.S. patent covering its catheter-based neuromodulation platform, expanding the company's intellectual property portfolio. The patented technology enhances the platform's ability to sense, map, and selectively target nerves associated with cancer pain and solid tumors, supporting the development of its investigational therapy for pancreatic cancer pain and broader oncology applications. Sector: Medical Devices / Biotechnology Key Highlights 📜 Granted a new U.S. patent for its neuromodulation platform 🩺 Technology enables nerve sensing, mapping, and targeted treatment 🎯 Focused on cancer pain and tumor-related nerve pathways 🧬 Supports development of therapies for pancreatic cancer pain and other oncology indications 🛡️ Strengthens the company's intellectual property portfolio Why It Matters The new patent reinforces Autonomix's competitive position in precision neuromodulation and supports the advancement of innovative, minimally invasive treatments for cancer-related pain. Read More: https://www.thinksabio.com/reports/isr/AMIX